|
WO2020210339A1
|
|
Hmox1 inducers
|
|
US2020131121A1
|
|
USP30 inhibitors
|
|
US2020131172A1
|
|
Dynamin-1-like protein inhibitors
|
|
WO2018125983A1
|
|
Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
|
|
CA3047137A1
|
|
Poly-adp ribose polymerase (parp) inhibitors
|
|
CN109843857A
|
|
The crystallization of PPAR agonist compound and salt form
|
|
SG11201901925RA
|
|
Methods of treating acute kidney injury
|
|
WO2018022851A1
|
|
Methods of treating acute kidney injury
|
|
CN109071459A
|
|
PPAR agonist, compound, pharmaceutical composition and their application method
|
|
US2019085008A1
|
|
Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
|
|
MX2018004295A
|
|
Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof.
|
|
WO2017044551A1
|
|
Ppar-alpha agonists for treating mitochondrial diseases
|
|
US2017305894A1
|
|
Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
|
|
WO2016057656A1
|
|
Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
|
|
US2017304255A1
|
|
PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
|
|
AU2014247953A1
|
|
PPAR agonists
|
